Skip to content

Study · Animal study (in vivo) · mouse · 2022

5 results

Melanocortin receptor agonist melanotan-II microinjected in the nucleus accumbens decreases appetitive and consumptive responding for food.

Eliason NL, Martin L, Low MJ, Sharpe AL

Neuropeptides16 Sept 2022Cited by 6 (Europe PMC)

PMID36155088 (opens in a new tab)PMCIDPMC10152796 (opens in a new tab)DOI10.1016/j.npep.2022.102289 (opens in a new tab)PepBankPUB-36155088
Source linkPubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In mice, MT-II microinjected into the nucleus accumbens decreased food consumption in the home cage paradigm.

    In plain wordsIn mice, MT-II injected into a brain area called the nucleus accumbens reduced food eaten in the home cage.

    Peptide
    Melanotan II
    Outcome
    DecreaseFood consumption in home cage
    Study

    mousen: not reported in source

    Male C57BL/6J mice, bilateral nucleus accumbens microinjection
    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    0.1, 0.3 and 1 nmol · microinjection into the nucleus accumbensAs given in this study (mouse).

    Source sentences

    Summary
    MT-II injected into the NAcc significantly decreased consumption in both home cage and operant paradigms, and furthermore decreased appetitive responding to gain access to food.
    1 context sentence
    Summary · context
    Male, C57BL/6J mice were microinjected bilaterally into the NAcc (100 nl/side) with the melanocortin receptor 3/4 agonist melanotan-II (MT-II; 0.1, 0.3, and 1 nmol), and ingestive behaviors were examined in both home cage and operant food self-administration experiments.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In mice, MT-II microinjected into the nucleus accumbens decreased food consumption in the operant paradigm.

    In plain wordsIn mice, MT-II injected into a brain area called the nucleus accumbens reduced food eaten in an operant task.

    Peptide
    Melanotan II
    Outcome
    DecreaseFood consumption in operant paradigm
    Study

    mousen: not reported in source

    Male C57BL/6J mice, bilateral nucleus accumbens microinjection
    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    0.1, 0.3 and 1 nmol · microinjection into the nucleus accumbensAs given in this study (mouse).

    Source sentences

    Summary
    MT-II injected into the NAcc significantly decreased consumption in both home cage and operant paradigms, and furthermore decreased appetitive responding to gain access to food.
    1 context sentence
    Summary · context
    Male, C57BL/6J mice were microinjected bilaterally into the NAcc (100 nl/side) with the melanocortin receptor 3/4 agonist melanotan-II (MT-II; 0.1, 0.3, and 1 nmol), and ingestive behaviors were examined in both home cage and operant food self-administration experiments.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In mice, MT-II microinjected into the nucleus accumbens decreased appetitive responding to gain access to food.

    In plain wordsIn mice, MT-II injected into a brain area called the nucleus accumbens reduced effort to get food.

    Peptide
    Melanotan II
    Outcome
    DecreaseAppetitive responding to gain access to food
    Study

    mousen: not reported in source

    Male C57BL/6J mice, bilateral nucleus accumbens microinjection
    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    0.1, 0.3 and 1 nmol · microinjection into the nucleus accumbensAs given in this study (mouse).

    Source sentences

    Summary
    and furthermore decreased appetitive responding to gain access to food.
    1 context sentence
    Summary · context
    Male, C57BL/6J mice were microinjected bilaterally into the NAcc (100 nl/side) with the melanocortin receptor 3/4 agonist melanotan-II (MT-II; 0.1, 0.3, and 1 nmol), and ingestive behaviors were examined in both home cage and operant food self-administration experiments.
  4. 04AnimalAnimal study (in vivo)Safety outcome

    In mice, anorexic doses of MT-II in the nucleus accumbens did not produce conditioned taste avoidance.

    In plain wordsIn mice, MT-II doses that reduced eating did not cause avoidance of a taste linked to the injection.

    Peptide
    Melanotan II
    Outcome
    No significant changeConditioned taste avoidance
    Study

    mousen: not reported in source

    Male C57BL/6J mice, bilateral nucleus accumbens microinjection
    Outcome group
    Adverse events · Nervous system and cognition
    Studied dose
    0.1, 0.3 and 1 nmol · microinjection into the nucleus accumbensAs given in this study (mouse).

    Source sentences

    Summary
    There was no development of conditioned taste avoidance
    2 context sentences
    Summary · context
    following anorexic doses of MT-II.
    Summary · context
    Male, C57BL/6J mice were microinjected bilaterally into the NAcc (100 nl/side) with the melanocortin receptor 3/4 agonist melanotan-II (MT-II; 0.1, 0.3, and 1 nmol), and ingestive behaviors were examined in both home cage and operant food self-administration experiments.
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In mice, anorexic doses of MT-II in the nucleus accumbens did not change metabolic parameters.

    In plain wordsIn mice, MT-II doses that reduced eating did not change measures of metabolism.

    Peptide
    Melanotan II
    Outcome
    No significant changeMetabolic parameters
    Study

    mousen: not reported in source

    Male C57BL/6J mice, bilateral nucleus accumbens microinjection
    Outcome group
    Energy expenditure and thermogenesis · Metabolic and weight
    Studied dose
    0.1, 0.3 and 1 nmol · microinjection into the nucleus accumbensAs given in this study (mouse).

    Source sentences

    Summary
    change in metabolic parameters following anorexic doses of MT-II.
    1 context sentence
    Summary · context
    Male, C57BL/6J mice were microinjected bilaterally into the NAcc (100 nl/side) with the melanocortin receptor 3/4 agonist melanotan-II (MT-II; 0.1, 0.3, and 1 nmol), and ingestive behaviors were examined in both home cage and operant food self-administration experiments.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 18:17 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.